Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Tolnaftate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 5/20 | 0.86 |
| ▸ | MAPT | P10636 | 4/20 | 0.86 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.86 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.86 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.86 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.86 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.86 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.86 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.86 |
| ▸ | HTR2B | P41595 | 1/20 | 0.86 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.86 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.43 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tolnaftate SCHEMBL8160019 | 0.93 | LMNA (1.00) | LMNAMAPTNR1I2TDP1CYP1A2 | |
| Tolnaftate SCHEMBL29484221 | 0.93 | LMNA (1.00) | LMNAMAPTNR1I2TDP1CYP1A2 | |
| Tolnaftate SCHEMBL30382951 | 0.93 | LMNA (1.00) | LMNAMAPTNR1I2TDP1CYP1A2 | |
| Tolnaftate SCHEMBL3520 | 0.93 | LMNA (1.00) | LMNAMAPTNR1I2TDP1CYP1A2 | |
| Tolnaftate SCHEMBL28341077 | 0.91 | LMNA (0.97) | LMNAMAPTNR1I2TDP1CYP1A2 | |
| Tolnaftate SCHEMBL22227756 | 0.91 | LMNA (0.97) | LMNAMAPTNR1I2TDP1CYP1A2 | |
| Tolnaftate SCHEMBL10897084 | 0.91 | LMNA (0.97) | LMNAMAPTNR1I2TDP1CYP1A2 | |
| Tolnaftate SCHEMBL893162 | 0.89 | LMNA (0.88) | LMNAMAPTNR1I2TDP1CYP1A2 | |
| Tolnaftate SCHEMBL3216288 | 0.88 | LMNA (0.86) | LMNAMAPTNR1I2TDP1CYP1A2 | |
| Tolnaftate SCHEMBL8985002 | 0.88 | LMNA (0.90) | LMNAMAPTNR1I2TDP1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116940351-A | Prodrug compositions and methods of treatment | 阿奎斯蒂弗医疗股份有限公司 | 2023-10-24 | — | — | CN | disclosed |